These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Utah
|
|
87-0327982
|
|
(State or other jurisdiction of
|
|
(IRS Employer
|
|
incorporation or organization)
|
|
Identification No.)
|
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
(Do not check if a smaller reporting company)
|
|
|
|
|
|
Emerging growth company
o
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
•
|
changes in laws and regulations, or their interpretation, applicable to direct selling or the nutritional supplement industry may prohibit or restrict the Company's ability to sell its products in some markets or require the Company to make changes to its business model in some markets;
|
|
•
|
legal challenges to its direct selling program or to the classification of its independent distributors;
|
|
•
|
complex legal and regulatory requirements in China, including the failure to obtain the necessary approvals and licenses to expand its direct sales activities in China;
|
|
•
|
extensive government regulations to which its products, business practices and manufacturing activities are subject;
|
|
•
|
the impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
|
|
•
|
the full implementation of its joint venture for operations in China with Fosun Industrial Co., Ltd.;
|
|
•
|
registration of products for sale in China, or difficulty or increased cost of importing products into China;
|
|
•
|
its business practices in some of the jurisdictions in which it operates, including China and South Korea, where the business practices may be legal and compliant with local and foreign law, but still draw unnecessary media or regulatory attention;
|
|
•
|
its ability to attract and retain independent distributors;
|
|
•
|
the effect of fluctuating foreign exchange rates;
|
|
•
|
negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of its customers to purchase products;
|
|
•
|
geopolitical issues and conflicts;
|
|
•
|
restrictions on the repatriation of money;
|
|
•
|
uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
|
|
•
|
changes in tax laws, treaties or regulations, or their interpretation;
|
|
•
|
taxation relating to its independent distributors;
|
|
•
|
high levels of inflation in one or more of the countries in which the Company operates;
|
|
•
|
cyber security threats and exposure to data loss;
|
|
•
|
reliance on information technology infrastructure;
|
|
•
|
liabilities and obligations arising from improper activity by its agents, employees or independent distributors;
|
|
•
|
its relationship with, and its inability to influence the actions of, its independent distributors, and other third parties with whom it does business;
|
|
•
|
its reliance upon, or the loss or departure of any member of, its senior management team;
|
|
•
|
challenges in managing rapid growth in China;
|
|
•
|
the slowing of the Chinese economy;
|
|
•
|
negative effects from its independent distributor promotions or compensation plans;
|
|
•
|
risks associated with the manufacturing of the Company's products;
|
|
•
|
availability and integrity of raw materials;
|
|
•
|
obsolescence of product inventory;
|
|
•
|
changing consumer preferences and demands;
|
|
•
|
the competitive nature of its business and the nutritional supplement industry;
|
|
•
|
negative publicity related to its products, ingredients, or direct selling organization and the nutritional supplement industry;
|
|
•
|
product liability claims;
|
|
•
|
the sufficiency of trademarks and other intellectual property rights; and
|
|
•
|
reliance on third-parties to distribute its products and provide support services to independent distributors.
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
|
Assets
|
|
|
|
|
|
||
|
Current assets:
|
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
31,821
|
|
|
$
|
32,284
|
|
|
Accounts receivable, net of allowance for doubtful accounts of $190 and $205, respectively
|
9,220
|
|
|
7,738
|
|
||
|
Investments available for sale
|
—
|
|
|
1,776
|
|
||
|
Assets held for sale
|
—
|
|
|
521
|
|
||
|
Inventories
|
50,958
|
|
|
47,597
|
|
||
|
Prepaid expenses and other
|
5,902
|
|
|
4,585
|
|
||
|
Total current assets
|
97,901
|
|
|
94,501
|
|
||
|
|
|
|
|
||||
|
Property, plant and equipment, net
|
72,662
|
|
|
73,272
|
|
||
|
Investment securities - trading
|
1,786
|
|
|
1,391
|
|
||
|
Intangible assets, net
|
1,007
|
|
|
976
|
|
||
|
Deferred income tax assets
|
21,391
|
|
|
21,590
|
|
||
|
Other assets
|
13,816
|
|
|
13,840
|
|
||
|
|
$
|
208,563
|
|
|
$
|
205,570
|
|
|
|
|
|
|
||||
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
5,361
|
|
|
$
|
5,305
|
|
|
Accrued volume incentives and service fees
|
17,654
|
|
|
16,264
|
|
||
|
Accrued liabilities
|
21,798
|
|
|
24,400
|
|
||
|
Deferred revenue
|
5,258
|
|
|
3,672
|
|
||
|
Revolving credit facility payable
|
11,954
|
|
|
9,919
|
|
||
|
Income taxes payable
|
2,795
|
|
|
3,475
|
|
||
|
Total current liabilities
|
64,820
|
|
|
63,035
|
|
||
|
|
|
|
|
||||
|
Liability related to unrecognized tax benefits
|
6,966
|
|
|
6,755
|
|
||
|
Deferred compensation payable
|
1,786
|
|
|
1,391
|
|
||
|
Other liabilities
|
1,307
|
|
|
1,991
|
|
||
|
Total liabilities
|
74,879
|
|
|
73,172
|
|
||
|
|
|
|
|
||||
|
Commitments and contingencies
|
|
|
|
|
|
||
|
|
|
|
|
||||
|
Shareholders’ equity:
|
|
|
|
|
|
||
|
Common stock, no par value, 50,000 shares authorized, 18,893 and 18,757 shares issued and outstanding, respectively
|
131,008
|
|
|
129,654
|
|
||
|
Retained earnings
|
12,805
|
|
|
12,718
|
|
||
|
Noncontrolling interests
|
756
|
|
|
1,286
|
|
||
|
Accumulated other comprehensive loss
|
(10,885
|
)
|
|
(11,260
|
)
|
||
|
Total shareholders’ equity
|
133,684
|
|
|
132,398
|
|
||
|
|
$
|
208,563
|
|
|
$
|
205,570
|
|
|
|
Three Months Ended
June 30, |
||||||
|
|
2017
|
|
2016
|
||||
|
Net sales
|
$
|
81,344
|
|
|
$
|
89,366
|
|
|
Cost of sales
|
21,197
|
|
|
23,078
|
|
||
|
Gross profit
|
60,147
|
|
|
66,288
|
|
||
|
|
|
|
|
||||
|
Operating expenses:
|
|
|
|
|
|
||
|
Volume incentives
|
28,288
|
|
|
30,791
|
|
||
|
Selling, general and administrative
|
31,836
|
|
|
31,249
|
|
||
|
Operating income
|
23
|
|
|
4,248
|
|
||
|
Other income (expense), net
|
441
|
|
|
(622
|
)
|
||
|
Income before provision for income taxes
|
464
|
|
|
3,626
|
|
||
|
Provision for income taxes
|
884
|
|
|
1,260
|
|
||
|
Net income (loss)
|
(420
|
)
|
|
2,366
|
|
||
|
Net loss attributable to noncontrolling interests
|
(233
|
)
|
|
(202
|
)
|
||
|
Net income (loss) attributable to common shareholders
|
$
|
(187
|
)
|
|
$
|
2,568
|
|
|
|
|
|
|
||||
|
Basic and diluted net income (loss) per common share:
|
|
|
|
|
|
||
|
|
|
|
|
||||
|
Basic earnings (loss) per share attributable to common shareholders
|
$
|
(0.01
|
)
|
|
$
|
0.14
|
|
|
|
|
|
|
||||
|
Diluted earnings (loss) per share attributable to common shareholders
|
$
|
(0.01
|
)
|
|
$
|
0.14
|
|
|
|
|
|
|
||||
|
Weighted average basic common shares outstanding
|
18,876
|
|
|
18,723
|
|
||
|
Weighted average diluted common shares outstanding
|
18,876
|
|
|
18,940
|
|
||
|
|
|
|
|
||||
|
Dividends declared per common share
|
$
|
—
|
|
|
$
|
0.10
|
|
|
|
Six Months Ended
June 30, |
||||||
|
|
2017
|
|
2016
|
||||
|
Net sales
|
$
|
164,442
|
|
|
$
|
171,768
|
|
|
Cost of sales
|
42,925
|
|
|
45,098
|
|
||
|
Gross profit
|
121,517
|
|
|
126,670
|
|
||
|
|
|
|
|
||||
|
Operating expenses:
|
|
|
|
|
|
||
|
Volume incentives
|
57,271
|
|
|
60,668
|
|
||
|
Selling, general and administrative
|
62,172
|
|
|
59,634
|
|
||
|
Operating income
|
2,074
|
|
|
6,368
|
|
||
|
Other income, net
|
1,716
|
|
|
937
|
|
||
|
Income before provision for income taxes
|
3,790
|
|
|
7,305
|
|
||
|
Provision for income taxes
|
2,347
|
|
|
3,150
|
|
||
|
Net income
|
1,443
|
|
|
4,155
|
|
||
|
Net loss attributable to noncontrolling interests
|
(530
|
)
|
|
(482
|
)
|
||
|
Net income attributable to common shareholders
|
$
|
1,973
|
|
|
$
|
4,637
|
|
|
|
|
|
|
||||
|
Basic and diluted net income per common share:
|
|
|
|
|
|
||
|
|
|
|
|
||||
|
Basic earnings per share attributable to common shareholders
|
$
|
0.10
|
|
|
$
|
0.25
|
|
|
|
|
|
|
||||
|
Diluted earnings per share attributable to common shareholders
|
$
|
0.10
|
|
|
$
|
0.24
|
|
|
|
|
|
|
||||
|
Weighted average basic common shares outstanding
|
18,861
|
|
|
18,708
|
|
||
|
Weighted average diluted common shares outstanding
|
19,251
|
|
|
18,946
|
|
||
|
|
|
|
|
||||
|
Dividends declared per common share
|
$
|
0.10
|
|
|
$
|
0.20
|
|
|
|
Three Months Ended
June 30, |
||||||
|
|
2017
|
|
2016
|
||||
|
Net income (loss)
|
$
|
(420
|
)
|
|
$
|
2,366
|
|
|
Foreign currency translation gain (loss), net of tax
|
(552
|
)
|
|
537
|
|
||
|
Net unrealized gains on investment securities (net of tax)
|
15
|
|
|
4
|
|
||
|
Total comprehensive income (loss)
|
$
|
(957
|
)
|
|
$
|
2,907
|
|
|
|
Six Months Ended
June 30, |
||||||
|
|
2017
|
|
2016
|
||||
|
Net income
|
$
|
1,443
|
|
|
$
|
4,155
|
|
|
Foreign currency translation gain (net of tax)
|
360
|
|
|
462
|
|
||
|
Net unrealized gains on investment securities (net of tax)
|
15
|
|
|
16
|
|
||
|
Total comprehensive income
|
$
|
1,818
|
|
|
$
|
4,633
|
|
|
|
Common Stock
|
|
Retained
Earnings
|
|
Noncontrolling
Interests
|
|
Accumulated
Other
Comprehensive
Income (Loss)
|
|
Total
|
|||||||||||||
|
|
Shares
|
|
Amount
|
|
|
|
|
|||||||||||||||
|
Balance at January 1, 2017
|
18,757
|
|
|
$
|
129,654
|
|
|
$
|
12,718
|
|
|
$
|
1,286
|
|
|
$
|
(11,260
|
)
|
|
$
|
132,398
|
|
|
Share-based compensation expense
|
—
|
|
|
1,762
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,762
|
|
|||||
|
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax
|
136
|
|
|
(408
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(408
|
)
|
|||||
|
Cash dividends ($0.10 per share)
|
—
|
|
|
—
|
|
|
(1,886
|
)
|
|
—
|
|
|
—
|
|
|
(1,886
|
)
|
|||||
|
Net income
|
—
|
|
|
—
|
|
|
1,973
|
|
|
(530
|
)
|
|
—
|
|
|
1,443
|
|
|||||
|
Other comprehensive income
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
375
|
|
|
375
|
|
|||||
|
Balance at June 30, 2017
|
18,893
|
|
|
$
|
131,008
|
|
|
$
|
12,805
|
|
|
$
|
756
|
|
|
$
|
(10,885
|
)
|
|
$
|
133,684
|
|
|
|
Six Months Ended
June 30, |
||||||
|
|
2017
|
|
2016
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
||
|
Net income
|
$
|
1,443
|
|
|
$
|
4,155
|
|
|
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
|
|
|
|
|
||
|
Provision for doubtful accounts
|
(22
|
)
|
|
62
|
|
||
|
Depreciation and amortization
|
3,585
|
|
|
2,396
|
|
||
|
Share-based compensation expense
|
1,762
|
|
|
1,586
|
|
||
|
(Gain) loss on sale of property and equipment
|
(10
|
)
|
|
78
|
|
||
|
Deferred income taxes
|
263
|
|
|
311
|
|
||
|
Purchase of trading investment securities
|
(367
|
)
|
|
(252
|
)
|
||
|
Proceeds from sale of trading investment securities
|
73
|
|
|
56
|
|
||
|
Realized and unrealized gains on investments
|
(79
|
)
|
|
(60
|
)
|
||
|
Foreign exchange gains
|
(1,882
|
)
|
|
(546
|
)
|
||
|
Changes in assets and liabilities:
|
|
|
|
|
|
||
|
Accounts receivable
|
(1,429
|
)
|
|
(164
|
)
|
||
|
Inventories
|
(2,359
|
)
|
|
(6,177
|
)
|
||
|
Prepaid expenses and other current assets
|
(1,221
|
)
|
|
(912
|
)
|
||
|
Other assets
|
358
|
|
|
(1,027
|
)
|
||
|
Accounts payable
|
109
|
|
|
2,402
|
|
||
|
Accrued volume incentives and service fees
|
1,082
|
|
|
2,798
|
|
||
|
Accrued liabilities
|
(3,542
|
)
|
|
950
|
|
||
|
Deferred revenue
|
1,586
|
|
|
735
|
|
||
|
Income taxes payable
|
(636
|
)
|
|
(150
|
)
|
||
|
Liability related to unrecognized tax benefits
|
207
|
|
|
231
|
|
||
|
Deferred compensation payable
|
395
|
|
|
(9
|
)
|
||
|
Net cash provided by (used in) operating activities
|
(684
|
)
|
|
6,463
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
||
|
Purchases of property, plant and equipment
|
(3,134
|
)
|
|
(4,592
|
)
|
||
|
Proceeds from sale of property, plant and equipment
|
522
|
|
|
—
|
|
||
|
Proceeds from sale/maturities of investments available for sale
|
1,776
|
|
|
—
|
|
||
|
Net cash used in investing activities
|
(836
|
)
|
|
(4,592
|
)
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
||
|
Payments of cash dividends
|
(1,886
|
)
|
|
(3,756
|
)
|
||
|
Net borrowings on revolving credit facility
|
2,035
|
|
|
1,224
|
|
||
|
Net proceeds from the exercise of stock options
|
104
|
|
|
59
|
|
||
|
Payment of withholding taxes related to the vesting of restricted stock units
|
(512
|
)
|
|
(169
|
)
|
||
|
Net cash used in financing activities
|
(259
|
)
|
|
(2,642
|
)
|
||
|
Effect of exchange rates on cash and cash equivalents
|
1,316
|
|
|
779
|
|
||
|
Net increase (decrease) in cash and cash equivalents
|
(463
|
)
|
|
8
|
|
||
|
Cash and cash equivalents at the beginning of the period
|
32,284
|
|
|
41,420
|
|
||
|
Cash and cash equivalents at the end of the period
|
$
|
31,821
|
|
|
$
|
41,428
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
|
|
|
|
|
|
||
|
Cash paid for income taxes
|
$
|
2,418
|
|
|
$
|
3,036
|
|
|
Cash paid for interest
|
108
|
|
|
122
|
|
||
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
|
Raw materials
|
$
|
12,969
|
|
|
$
|
14,995
|
|
|
Work in progress
|
1,141
|
|
|
694
|
|
||
|
Finished goods
|
36,848
|
|
|
31,908
|
|
||
|
Total inventory
|
$
|
50,958
|
|
|
$
|
47,597
|
|
|
As of December 31, 2016
|
Amortized
Cost
|
|
Gross
Unrealized
Gains
|
|
Gross
Unrealized
Losses
|
|
Fair
Value
|
||||||||
|
U.S. government securities funds
|
$
|
1,799
|
|
|
$
|
—
|
|
|
$
|
(23
|
)
|
|
$
|
1,776
|
|
|
Total short-term investment securities
|
$
|
1,799
|
|
|
$
|
—
|
|
|
$
|
(23
|
)
|
|
$
|
1,776
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net income (loss) attributable to common shareholders
|
$
|
(187
|
)
|
|
$
|
2,568
|
|
|
$
|
1,973
|
|
|
$
|
4,637
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Basic weighted average shares outstanding
|
18,876
|
|
|
18,723
|
|
|
18,861
|
|
|
18,708
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Basic earnings (loss) per share attributable to common shareholders
|
$
|
(0.01
|
)
|
|
$
|
0.14
|
|
|
$
|
0.10
|
|
|
$
|
0.25
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted shares outstanding
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Basic weighted-average shares outstanding
|
18,876
|
|
|
18,723
|
|
|
18,861
|
|
|
18,708
|
|
||||
|
Stock-based awards
|
—
|
|
|
217
|
|
|
390
|
|
|
238
|
|
||||
|
Diluted weighted-average shares outstanding
|
18,876
|
|
|
18,940
|
|
|
19,251
|
|
|
18,946
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Diluted earnings (loss) per share attributable to common shareholders
|
$
|
(0.01
|
)
|
|
$
|
0.14
|
|
|
$
|
0.10
|
|
|
$
|
0.24
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Stock options
|
—
|
|
(1)
|
86
|
|
|
371
|
|
|
86
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Anti-dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Stock options
|
2,444
|
|
(1)
|
1,445
|
|
|
1,363
|
|
|
1,445
|
|
||||
|
|
Number of
Shares
|
|
Weighted Average
Exercise
Price Per Share
|
|||
|
Options outstanding at December 31, 2016
|
1,524
|
|
|
$
|
12.41
|
|
|
Granted
|
25
|
|
|
13.50
|
|
|
|
Forfeited or canceled
|
—
|
|
|
—
|
|
|
|
Exercised
|
(9
|
)
|
|
11.98
|
|
|
|
Options outstanding at June 30, 2017
|
1,540
|
|
|
12.34
|
|
|
|
|
Number of
Shares
|
|
Weighted Average
Grant Date
Fair Value
|
|||
|
Restricted Stock Units outstanding at December 31, 2016
|
838
|
|
|
$
|
11.39
|
|
|
Granted
|
256
|
|
|
12.69
|
|
|
|
Forfeited
|
(25
|
)
|
|
12.37
|
|
|
|
Issued
|
(165
|
)
|
|
12.16
|
|
|
|
Restricted Stock Units outstanding at June 30, 2017
|
904
|
|
|
11.68
|
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net sales:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
NSP Americas
|
$
|
39,421
|
|
|
$
|
44,725
|
|
|
$
|
84,066
|
|
|
$
|
89,908
|
|
|
NSP Russia, Central and Eastern Europe
|
6,662
|
|
|
6,269
|
|
|
14,269
|
|
|
12,621
|
|
||||
|
Synergy WorldWide
|
30,363
|
|
|
33,013
|
|
|
57,676
|
|
|
62,861
|
|
||||
|
China and New Markets
|
4,898
|
|
|
5,359
|
|
|
8,431
|
|
|
6,378
|
|
||||
|
Total net sales
|
81,344
|
|
|
89,366
|
|
|
164,442
|
|
|
171,768
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Contribution margin (1):
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
NSP Americas
|
16,495
|
|
|
19,103
|
|
|
35,690
|
|
|
38,020
|
|
||||
|
NSP Russia, Central and Eastern Europe
|
2,246
|
|
|
2,065
|
|
|
4,755
|
|
|
4,246
|
|
||||
|
Synergy WorldWide
|
9,410
|
|
|
10,245
|
|
|
17,609
|
|
|
19,184
|
|
||||
|
China and New Markets
|
3,708
|
|
|
4,084
|
|
|
6,192
|
|
|
4,552
|
|
||||
|
Total contribution margin
|
31,859
|
|
|
35,497
|
|
|
64,246
|
|
|
66,002
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Selling, general and administrative expenses (2)
|
31,836
|
|
|
31,249
|
|
|
62,172
|
|
|
59,634
|
|
||||
|
Operating income
|
23
|
|
|
4,248
|
|
|
2,074
|
|
|
6,368
|
|
||||
|
|
|
|
|
|
|
|
|
||||||||
|
Other income (expense), net
|
441
|
|
|
(622
|
)
|
|
1,716
|
|
|
937
|
|
||||
|
Income from continuing operations before provision for income taxes
|
$
|
464
|
|
|
$
|
3,626
|
|
|
$
|
3,790
|
|
|
$
|
7,305
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
Net sales:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
United States
|
$
|
33,805
|
|
|
$
|
37,598
|
|
|
$
|
71,540
|
|
|
$
|
75,893
|
|
|
South Korea
|
12,486
|
|
|
15,473
|
|
|
23,832
|
|
|
28,671
|
|
||||
|
Other
|
35,053
|
|
|
36,295
|
|
|
69,070
|
|
|
67,204
|
|
||||
|
|
$
|
81,344
|
|
|
$
|
89,366
|
|
|
$
|
164,442
|
|
|
$
|
171,768
|
|
|
|
Three Months Ended
June 30, |
|
Six Months Ended
June 30, |
||||||||||||
|
|
2017
|
|
2016
|
|
2017
|
|
2016
|
||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General health
|
$
|
18,181
|
|
|
$
|
20,234
|
|
|
$
|
38,047
|
|
|
$
|
39,851
|
|
|
Immune
|
3,169
|
|
|
3,738
|
|
|
8,242
|
|
|
9,314
|
|
||||
|
Cardiovascular
|
2,820
|
|
|
3,418
|
|
|
6,136
|
|
|
6,530
|
|
||||
|
Digestive
|
11,660
|
|
|
11,845
|
|
|
23,808
|
|
|
24,924
|
|
||||
|
Personal care
|
1,487
|
|
|
2,853
|
|
|
3,373
|
|
|
3,783
|
|
||||
|
Weight management
|
2,104
|
|
|
2,637
|
|
|
4,460
|
|
|
5,506
|
|
||||
|
|
39,421
|
|
|
44,725
|
|
|
84,066
|
|
|
89,908
|
|
||||
|
NSP Russia, Eastern and Central Europe:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General health
|
$
|
2,941
|
|
|
$
|
2,501
|
|
|
$
|
6,499
|
|
|
$
|
5,224
|
|
|
Immune
|
638
|
|
|
857
|
|
|
1,401
|
|
|
1,397
|
|
||||
|
Cardiovascular
|
480
|
|
|
493
|
|
|
1,011
|
|
|
970
|
|
||||
|
Digestive
|
2,030
|
|
|
1,407
|
|
|
3,907
|
|
|
3,528
|
|
||||
|
Personal care
|
424
|
|
|
853
|
|
|
1,032
|
|
|
1,102
|
|
||||
|
Weight management
|
149
|
|
|
158
|
|
|
419
|
|
|
400
|
|
||||
|
|
6,662
|
|
|
6,269
|
|
|
14,269
|
|
|
12,621
|
|
||||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General health
|
$
|
7,624
|
|
|
$
|
9,694
|
|
|
$
|
14,311
|
|
|
$
|
18,334
|
|
|
Immune
|
117
|
|
|
41
|
|
|
238
|
|
|
250
|
|
||||
|
Cardiovascular
|
12,603
|
|
|
13,505
|
|
|
23,706
|
|
|
26,198
|
|
||||
|
Digestive
|
4,154
|
|
|
3,442
|
|
|
7,619
|
|
|
5,929
|
|
||||
|
Personal care
|
1,926
|
|
|
1,948
|
|
|
3,993
|
|
|
3,887
|
|
||||
|
Weight management
|
3,939
|
|
|
4,383
|
|
|
7,809
|
|
|
8,263
|
|
||||
|
|
30,363
|
|
|
33,013
|
|
|
57,676
|
|
|
62,861
|
|
||||
|
China and New Markets:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
General health
|
$
|
1,085
|
|
|
$
|
1,537
|
|
|
$
|
1,965
|
|
|
$
|
2,008
|
|
|
Immune
|
120
|
|
|
216
|
|
|
266
|
|
|
347
|
|
||||
|
Cardiovascular
|
972
|
|
|
1,450
|
|
|
1,553
|
|
|
1,523
|
|
||||
|
Digestive
|
1,813
|
|
|
1,262
|
|
|
3,455
|
|
|
1,522
|
|
||||
|
Personal care
|
45
|
|
|
439
|
|
|
121
|
|
|
461
|
|
||||
|
Weight management
|
863
|
|
|
455
|
|
|
1,071
|
|
|
517
|
|
||||
|
|
4,898
|
|
|
5,359
|
|
|
8,431
|
|
|
6,378
|
|
||||
|
|
$
|
81,344
|
|
|
$
|
89,366
|
|
|
$
|
164,442
|
|
|
$
|
171,768
|
|
|
|
June 30,
2017 |
|
December 31,
2016 |
||||
|
Property, plant and equipment:
|
|
|
|
|
|
||
|
United States
|
$
|
69,876
|
|
|
$
|
70,770
|
|
|
Other
|
2,786
|
|
|
2,502
|
|
||
|
Total property, plant and equipment
|
$
|
72,662
|
|
|
$
|
73,272
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
|
Total
|
||||||||
|
Trading Investment securities
|
1,786
|
|
|
—
|
|
|
—
|
|
|
1,786
|
|
||||
|
Total assets measured at fair value on a recurring basis
|
$
|
1,786
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,786
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
|
Total
|
||||||||
|
Investments available-for-sale
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
U.S. government security funds
|
$
|
1,776
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,776
|
|
|
Trading Investment securities
|
1,391
|
|
|
—
|
|
|
—
|
|
|
1,391
|
|
||||
|
Total assets measured at fair value on a recurring basis
|
$
|
3,167
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
3,167
|
|
|
|
Three Months Ended
June 30, 2017 |
|
Three Months Ended
June 30, 2016 |
|
Change
|
|||||||||||||||
|
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percentage
|
|||||||||
|
Net sales
|
$
|
81,344
|
|
|
100.0
|
%
|
|
$
|
89,366
|
|
|
100.0
|
%
|
|
$
|
(8,022
|
)
|
|
(9.0
|
)%
|
|
Cost of sales
|
21,197
|
|
|
26.1
|
|
|
23,078
|
|
|
25.8
|
|
|
(1,881
|
)
|
|
(8.2
|
)
|
|||
|
|
60,147
|
|
|
73.9
|
|
|
66,288
|
|
|
74.2
|
|
|
(6,141
|
)
|
|
(9.3
|
)
|
|||
|
Volume incentives
|
28,288
|
|
|
34.8
|
|
|
30,791
|
|
|
34.5
|
|
|
(2,503
|
)
|
|
(8.1
|
)
|
|||
|
SG&A expenses
|
31,836
|
|
|
39.1
|
|
|
31,249
|
|
|
35.0
|
|
|
587
|
|
|
1.9
|
|
|||
|
Operating income
|
23
|
|
|
—
|
|
|
4,248
|
|
|
4.8
|
|
|
(4,225
|
)
|
|
(99.5
|
)
|
|||
|
Other income (expense), net
|
441
|
|
|
0.5
|
|
|
(622
|
)
|
|
(0.7
|
)
|
|
1,063
|
|
|
170.9
|
|
|||
|
Income from continuing operations before income taxes
|
464
|
|
|
0.6
|
|
|
3,626
|
|
|
4.1
|
|
|
(3,162
|
)
|
|
(87.2
|
)
|
|||
|
Provision for income taxes
|
884
|
|
|
1.1
|
|
|
1,260
|
|
|
1.4
|
|
|
(376
|
)
|
|
(29.8
|
)
|
|||
|
Net income (loss)
|
$
|
(420
|
)
|
|
(0.5
|
)%
|
|
$
|
2,366
|
|
|
2.6
|
%
|
|
$
|
(2,786
|
)
|
|
(117.8
|
)%
|
|
|
Six Months Ended
June 30, 2017 |
|
Six Months Ended
June 30, 2016 |
|
Change
|
|||||||||||||||
|
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percentage
|
|||||||||
|
Net sales
|
$
|
164,442
|
|
|
100.0
|
%
|
|
$
|
171,768
|
|
|
100.0
|
%
|
|
$
|
(7,326
|
)
|
|
(4.3
|
)%
|
|
Cost of sales
|
42,925
|
|
|
26.1
|
|
|
45,098
|
|
|
26.3
|
|
|
(2,173
|
)
|
|
(4.8
|
)
|
|||
|
|
121,517
|
|
|
73.9
|
|
|
126,670
|
|
|
73.7
|
|
|
(5,153
|
)
|
|
(4.1
|
)
|
|||
|
Volume incentives
|
57,271
|
|
|
34.8
|
|
|
60,668
|
|
|
35.3
|
|
|
(3,397
|
)
|
|
(5.6
|
)
|
|||
|
SG&A expenses
|
62,172
|
|
|
37.8
|
|
|
59,634
|
|
|
34.7
|
|
|
2,538
|
|
|
4.3
|
|
|||
|
Operating income
|
2,074
|
|
|
1.3
|
|
|
6,368
|
|
|
3.7
|
|
|
(4,294
|
)
|
|
(67.4
|
)
|
|||
|
Other income, net
|
1,716
|
|
|
1.0
|
|
|
937
|
|
|
0.5
|
|
|
779
|
|
|
83.1
|
|
|||
|
Income from continuing operations before income taxes
|
3,790
|
|
|
2.3
|
|
|
7,305
|
|
|
4.3
|
|
|
(3,515
|
)
|
|
(48.1
|
)
|
|||
|
Provision for income taxes
|
2,347
|
|
|
1.4
|
|
|
3,150
|
|
|
1.8
|
|
|
(803
|
)
|
|
(25.5
|
)
|
|||
|
Net income
|
$
|
1,443
|
|
|
0.9
|
%
|
|
$
|
4,155
|
|
|
2.4
|
%
|
|
$
|
(2,712
|
)
|
|
(65.3
|
)%
|
|
|
Net Sales by Operating Segment
|
||||||||||||||||
|
|
Three Months Ended
June 30, 2017 |
|
Three Months Ended
June 30, 2016 |
|
Percent
Change |
|
Impact of
Currency Exchange |
|
Percent
Change Excluding Impact of Currency |
||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
NSP North America
|
$
|
33,190
|
|
|
$
|
37,439
|
|
|
(11.3
|
)%
|
|
$
|
(117
|
)
|
|
(11.0
|
)%
|
|
NSP Latin America
|
6,231
|
|
|
7,286
|
|
|
(14.5
|
)
|
|
(37
|
)
|
|
(14.0
|
)
|
|||
|
|
39,421
|
|
|
44,725
|
|
|
(11.9
|
)
|
|
(154
|
)
|
|
(11.5
|
)
|
|||
|
NSP Russia, Central and Eastern Europe
|
6,662
|
|
|
6,269
|
|
|
6.3
|
|
|
12
|
|
|
6.1
|
|
|||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Synergy Asia Pacific
|
21,271
|
|
|
23,397
|
|
|
(9.1
|
)
|
|
217
|
|
|
(10.0
|
)
|
|||
|
Synergy Europe
|
6,097
|
|
|
6,738
|
|
|
(9.5
|
)
|
|
(165
|
)
|
|
(7.1
|
)
|
|||
|
Synergy North America
|
2,995
|
|
|
2,878
|
|
|
4.1
|
|
|
—
|
|
|
4.1
|
|
|||
|
|
30,363
|
|
|
33,013
|
|
|
(8.0
|
)
|
|
52
|
|
|
(8.2
|
)
|
|||
|
China and New Markets
|
4,898
|
|
|
5,359
|
|
|
(8.6
|
)
|
|
—
|
|
|
(8.6
|
)
|
|||
|
|
$
|
81,344
|
|
|
$
|
89,366
|
|
|
(9.0
|
)%
|
|
$
|
(90
|
)
|
|
(8.9
|
)%
|
|
|
Net Sales by Operating Segment
|
||||||||||||||||
|
|
Six Months Ended
June 30, 2017 |
|
Six Months Ended
June 30, 2016 |
|
Percent
Change |
|
Impact of
Currency Exchange |
|
Percent
Change Excluding Impact of Currency |
||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
NSP North America
|
$
|
71,236
|
|
|
$
|
75,745
|
|
|
(6.0
|
)%
|
|
$
|
(21
|
)
|
|
(5.9
|
)%
|
|
NSP Latin America
|
12,830
|
|
|
14,163
|
|
|
(9.4
|
)
|
|
(121
|
)
|
|
(8.6
|
)
|
|||
|
|
84,066
|
|
|
89,908
|
|
|
(6.5
|
)
|
|
(142
|
)
|
|
(6.3
|
)
|
|||
|
NSP Russia, Central and Eastern Europe
|
14,269
|
|
|
12,621
|
|
|
13.1
|
|
|
(17
|
)
|
|
13.2
|
|
|||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Synergy Asia Pacific
|
40,052
|
|
|
44,213
|
|
|
(9.4
|
)
|
|
810
|
|
|
(11.2
|
)
|
|||
|
Synergy Europe
|
12,022
|
|
|
12,994
|
|
|
(7.5
|
)
|
|
(380
|
)
|
|
(4.6
|
)
|
|||
|
Synergy North America
|
5,602
|
|
|
5,654
|
|
|
(0.9
|
)
|
|
—
|
|
|
(0.9
|
)
|
|||
|
|
57,676
|
|
|
62,861
|
|
|
(8.2
|
)
|
|
430
|
|
|
(8.9
|
)
|
|||
|
China and New Markets
|
8,431
|
|
|
6,378
|
|
|
32.2
|
|
|
—
|
|
|
32.2
|
|
|||
|
|
$
|
164,442
|
|
|
$
|
171,768
|
|
|
(4.3
|
)%
|
|
$
|
271
|
|
|
(4.4
|
)%
|
|
•
|
$0.5 million and $1.8 million of increased investment in China during the
three and six
months ended
June 30, 2017
, respectively;
|
|
•
|
$1.2 million of increased depreciation related to the Oracle ERP implementation project incurred for the
three and six
months ended
June 30, 2017
;
|
|
•
|
$0.7 million reduction of reserves for product liability for the
three and six
months ended
June 30, 2017
.
|
|
Three Months Ended June 30,
|
2017
|
|
2016
|
||||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
18,181
|
|
|
46.1
|
%
|
|
$
|
20,234
|
|
|
45.2
|
%
|
|
Immune
|
3,169
|
|
|
8.0
|
|
|
3,738
|
|
|
8.4
|
|
||
|
Cardiovascular
|
2,820
|
|
|
7.2
|
|
|
3,418
|
|
|
7.6
|
|
||
|
Digestive
|
11,660
|
|
|
29.6
|
|
|
11,845
|
|
|
26.5
|
|
||
|
Personal care
|
1,487
|
|
|
3.8
|
|
|
2,853
|
|
|
6.4
|
|
||
|
Weight management
|
2,104
|
|
|
5.3
|
|
|
2,637
|
|
|
5.9
|
|
||
|
Total NSP Americas
|
39,421
|
|
|
100.0
|
|
|
44,725
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
NSP Russia, Central and Eastern Europe:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
2,941
|
|
|
44.1
|
%
|
|
$
|
2,501
|
|
|
39.9
|
%
|
|
Immune
|
638
|
|
|
9.6
|
|
|
857
|
|
|
13.7
|
|
||
|
Cardiovascular
|
480
|
|
|
7.2
|
|
|
493
|
|
|
7.9
|
|
||
|
Digestive
|
2,030
|
|
|
30.5
|
|
|
1,407
|
|
|
22.4
|
|
||
|
Personal care
|
424
|
|
|
6.4
|
|
|
853
|
|
|
13.6
|
|
||
|
Weight management
|
149
|
|
|
2.2
|
|
|
158
|
|
|
2.5
|
|
||
|
Total NSP Russia, Central and Eastern Europe
|
6,662
|
|
|
100.0
|
|
|
6,269
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
7,624
|
|
|
25.1
|
%
|
|
$
|
9,694
|
|
|
29.4
|
%
|
|
Immune
|
117
|
|
|
0.4
|
|
|
41
|
|
|
0.1
|
|
||
|
Cardiovascular
|
12,603
|
|
|
41.5
|
|
|
13,505
|
|
|
40.9
|
|
||
|
Digestive
|
4,154
|
|
|
13.7
|
|
|
3,442
|
|
|
10.4
|
|
||
|
Personal care
|
1,926
|
|
|
6.3
|
|
|
1,948
|
|
|
5.9
|
|
||
|
Weight management
|
3,939
|
|
|
13.0
|
|
|
4,383
|
|
|
13.3
|
|
||
|
Total Synergy WorldWide
|
30,363
|
|
|
100.0
|
|
|
33,013
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
China and New Markets:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
1,085
|
|
|
22.2
|
%
|
|
$
|
1,537
|
|
|
28.7
|
%
|
|
Immune
|
120
|
|
|
2.4
|
|
|
216
|
|
|
4.0
|
|
||
|
Cardiovascular
|
972
|
|
|
19.8
|
|
|
1,450
|
|
|
27.1
|
|
||
|
Digestive
|
1,813
|
|
|
37.0
|
|
|
1,262
|
|
|
23.5
|
|
||
|
Personal care
|
45
|
|
|
0.9
|
|
|
439
|
|
|
8.2
|
|
||
|
Weight management
|
863
|
|
|
17.6
|
|
|
455
|
|
|
8.5
|
|
||
|
Total China and New Markets
|
4,898
|
|
|
100.0
|
|
|
5,359
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
29,831
|
|
|
36.7
|
%
|
|
$
|
33,966
|
|
|
38.0
|
%
|
|
Immune
|
4,044
|
|
|
5.0
|
|
|
4,852
|
|
|
5.4
|
|
||
|
Cardiovascular
|
16,875
|
|
|
20.7
|
|
|
18,866
|
|
|
21.1
|
|
||
|
Digestive
|
19,657
|
|
|
24.2
|
|
|
17,956
|
|
|
20.1
|
|
||
|
Personal care
|
3,882
|
|
|
4.8
|
|
|
6,093
|
|
|
6.8
|
|
||
|
Weight management
|
7,055
|
|
|
8.7
|
|
|
7,633
|
|
|
8.5
|
|
||
|
Total Consolidated
|
$
|
81,344
|
|
|
100.0
|
%
|
|
$
|
89,366
|
|
|
100.0
|
%
|
|
Six Months Ended June 30,
|
2017
|
|
2016
|
||||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
38,047
|
|
|
45.3
|
%
|
|
$
|
39,851
|
|
|
44.3
|
%
|
|
Immune
|
8,242
|
|
|
9.8
|
|
|
9,314
|
|
|
10.4
|
|
||
|
Cardiovascular
|
6,136
|
|
|
7.3
|
|
|
6,530
|
|
|
7.3
|
|
||
|
Digestive
|
23,808
|
|
|
28.3
|
|
|
24,924
|
|
|
27.7
|
|
||
|
Personal care
|
3,373
|
|
|
4.0
|
|
|
3,783
|
|
|
4.2
|
|
||
|
Weight management
|
4,460
|
|
|
5.3
|
|
|
5,506
|
|
|
6.1
|
|
||
|
Total NSP Americas
|
84,066
|
|
|
100.0
|
|
|
89,908
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
NSP Russia, Central and Eastern Europe:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
6,499
|
|
|
45.5
|
%
|
|
$
|
5,224
|
|
|
41.4
|
%
|
|
Immune
|
1,401
|
|
|
9.8
|
|
|
1,397
|
|
|
11.1
|
|
||
|
Cardiovascular
|
1,011
|
|
|
7.1
|
|
|
970
|
|
|
7.7
|
|
||
|
Digestive
|
3,907
|
|
|
27.4
|
|
|
3,528
|
|
|
28.0
|
|
||
|
Personal care
|
1,032
|
|
|
7.2
|
|
|
1,102
|
|
|
8.7
|
|
||
|
Weight management
|
419
|
|
|
2.9
|
|
|
400
|
|
|
3.2
|
|
||
|
Total NSP Russia, Central and Eastern Europe
|
14,269
|
|
|
100.0
|
|
|
12,621
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
14,311
|
|
|
24.8
|
%
|
|
$
|
18,334
|
|
|
29.2
|
%
|
|
Immune
|
238
|
|
|
0.4
|
|
|
250
|
|
|
0.4
|
|
||
|
Cardiovascular
|
23,706
|
|
|
41.1
|
|
|
26,198
|
|
|
41.7
|
|
||
|
Digestive
|
7,619
|
|
|
13.2
|
|
|
5,929
|
|
|
9.4
|
|
||
|
Personal care
|
3,993
|
|
|
6.9
|
|
|
3,887
|
|
|
6.2
|
|
||
|
Weight management
|
7,809
|
|
|
13.5
|
|
|
8,263
|
|
|
13.1
|
|
||
|
Total Synergy WorldWide
|
57,676
|
|
|
100.0
|
|
|
62,861
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
China and New Markets:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
1,965
|
|
|
23.3
|
%
|
|
$
|
2,008
|
|
|
31.5
|
%
|
|
Immune
|
266
|
|
|
3.2
|
|
|
347
|
|
|
5.4
|
|
||
|
Cardiovascular
|
1,553
|
|
|
18.4
|
|
|
1,523
|
|
|
23.9
|
|
||
|
Digestive
|
3,455
|
|
|
41.0
|
|
|
1,522
|
|
|
23.9
|
|
||
|
Personal care
|
121
|
|
|
1.4
|
|
|
461
|
|
|
7.2
|
|
||
|
Weight management
|
1,071
|
|
|
12.7
|
|
|
517
|
|
|
8.1
|
|
||
|
Total China and New Markets
|
8,431
|
|
|
100.0
|
|
|
6,378
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
60,822
|
|
|
37.0
|
%
|
|
$
|
65,417
|
|
|
38.1
|
%
|
|
Immune
|
10,147
|
|
|
6.2
|
|
|
11,308
|
|
|
6.6
|
|
||
|
Cardiovascular
|
32,406
|
|
|
19.7
|
|
|
35,221
|
|
|
20.5
|
|
||
|
Digestive
|
38,789
|
|
|
23.6
|
|
|
35,903
|
|
|
20.9
|
|
||
|
Personal care
|
8,519
|
|
|
5.2
|
|
|
9,233
|
|
|
5.4
|
|
||
|
Weight management
|
13,759
|
|
|
8.4
|
|
|
14,686
|
|
|
8.5
|
|
||
|
Total Consolidated
|
$
|
164,442
|
|
|
100.0
|
%
|
|
$
|
171,768
|
|
|
100.0
|
%
|
|
|
2017
|
|
2016
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
253,300
|
|
|
6,400
|
|
|
280,400
|
|
|
7,000
|
|
|
NSP Russia, Central and Eastern Europe
|
138,700
|
|
|
2,700
|
|
|
149,500
|
|
|
2,400
|
|
|
Synergy WorldWide
|
111,100
|
|
|
4,100
|
|
|
124,600
|
|
|
3,800
|
|
|
|
503,100
|
|
|
13,200
|
|
|
554,500
|
|
|
13,200
|
|
|
|
2017
|
|
2016
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
105,500
|
|
|
6,400
|
|
|
129,700
|
|
|
7,000
|
|
|
NSP Russia, Central and Eastern Europe
|
60,000
|
|
|
2,700
|
|
|
62,600
|
|
|
2,400
|
|
|
Synergy WorldWide
|
49,000
|
|
|
4,100
|
|
|
56,600
|
|
|
3,800
|
|
|
|
214,500
|
|
|
13,200
|
|
|
248,900
|
|
|
13,200
|
|
|
|
2017
|
|
2016
|
||||||||
|
|
New Distributors
& Customers |
|
New Managers
|
|
New Distributors
& Customers |
|
New Managers
|
||||
|
NSP Americas
|
19,200
|
|
|
500
|
|
|
30,800
|
|
|
700
|
|
|
NSP Russia, Central and Eastern Europe
|
11,100
|
|
|
200
|
|
|
10,800
|
|
|
200
|
|
|
Synergy WorldWide
|
15,900
|
|
|
600
|
|
|
19,100
|
|
|
700
|
|
|
|
46,200
|
|
|
1,300
|
|
|
60,700
|
|
|
1,600
|
|
|
|
2017
|
|
2016
|
||||||||
|
|
New Distributors
& Customers |
|
New Managers
|
|
New Distributors
& Customers |
|
New Managers
|
||||
|
NSP Americas
|
103,100
|
|
|
2,400
|
|
|
124,900
|
|
|
2,900
|
|
|
NSP Russia, Central and Eastern Europe
|
46,800
|
|
|
600
|
|
|
45,200
|
|
|
600
|
|
|
Synergy WorldWide
|
63,000
|
|
|
3,000
|
|
|
76,400
|
|
|
2,600
|
|
|
|
212,900
|
|
|
6,000
|
|
|
246,500
|
|
|
6,100
|
|
|
|
Six Months Ended June 30,
|
||||||
|
|
2017
|
|
2016
|
||||
|
Operating activities
|
$
|
(684
|
)
|
|
$
|
6,463
|
|
|
Investing activities
|
(836
|
)
|
|
(4,592
|
)
|
||
|
Financing activities
|
(259
|
)
|
|
(2,642
|
)
|
||
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|||||||||||
|
Net sales
|
$
|
81,344
|
|
|
(3,543
|
)
|
|
(4.4
|
)%
|
|
$
|
(5,083
|
)
|
|
(6.2
|
)%
|
|
$
|
(7,795
|
)
|
|
(9.6
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Cost and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of sales
|
21,197
|
|
|
(1,108
|
)
|
|
(5.2
|
)
|
|
(1,590
|
)
|
|
(7.5
|
)
|
|
(2,438
|
)
|
|
(11.5
|
)
|
||||
|
Volume incentives
|
28,288
|
|
|
(1,387
|
)
|
|
(4.9
|
)
|
|
(1,991
|
)
|
|
(7.0
|
)
|
|
(3,053
|
)
|
|
(10.8
|
)
|
||||
|
Selling, general and administrative
|
31,836
|
|
|
(979
|
)
|
|
(3.1
|
)
|
|
(1,405
|
)
|
|
(4.4
|
)
|
|
(2,155
|
)
|
|
(6.8
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Operating loss
|
$
|
23
|
|
|
$
|
(69
|
)
|
|
(300.0
|
)%
|
|
$
|
(97
|
)
|
|
(421.7
|
)%
|
|
$
|
(149
|
)
|
|
(647.8
|
)%
|
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|||||||||||
|
Net sales
|
$
|
164,442
|
|
|
(6,760
|
)
|
|
(4.1
|
)%
|
|
$
|
(9,699
|
)
|
|
(5.9
|
)%
|
|
$
|
(14,872
|
)
|
|
(9.0
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Cost and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of sales
|
42,925
|
|
|
(2,129
|
)
|
|
(5.0
|
)
|
|
(3,055
|
)
|
|
(7.1
|
)
|
|
(4,685
|
)
|
|
(10.9
|
)
|
||||
|
Volume incentives
|
57,271
|
|
|
(2,578
|
)
|
|
(4.5
|
)
|
|
(3,700
|
)
|
|
(6.5
|
)
|
|
(5,673
|
)
|
|
(9.9
|
)
|
||||
|
Selling, general and administrative
|
62,172
|
|
|
(1,945
|
)
|
|
(3.1
|
)
|
|
(2,791
|
)
|
|
(4.5
|
)
|
|
(4,280
|
)
|
|
(6.9
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Operating income
|
$
|
2,074
|
|
|
$
|
(108
|
)
|
|
(5.2
|
)%
|
|
$
|
(153
|
)
|
|
(7.4
|
)%
|
|
$
|
(234
|
)
|
|
(11.3
|
)%
|
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|||||||||||
|
Financial Instruments Included in Current Assets Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
31,821
|
|
|
$
|
(2,299
|
)
|
|
(7.2
|
)%
|
|
$
|
(3,299
|
)
|
|
(10.4
|
)%
|
|
$
|
(5,058
|
)
|
|
(15.9
|
)%
|
|
Accounts receivable, net
|
9,220
|
|
|
(231
|
)
|
|
(2.5
|
)
|
|
(331
|
)
|
|
(3.6
|
)
|
|
(508
|
)
|
|
(5.5
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Financial Instruments Included in Current Liabilities Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Accounts payable
|
5,361
|
|
|
(109
|
)
|
|
(2.0
|
)
|
|
(157
|
)
|
|
(2.9
|
)
|
|
(240
|
)
|
|
(4.5
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Net Financial Instruments Subject to Exchange Rate Risk
|
$
|
35,680
|
|
|
$
|
(2,421
|
)
|
|
(6.8
|
)%
|
|
$
|
(3,473
|
)
|
|
(9.7
|
)%
|
|
$
|
(5,326
|
)
|
|
(14.9
|
)%
|
|
|
|
Translated into U.S.
Dollars |
|
At Spot Exchange Rate
per One U.S. Dollar as of September 30, 2016 |
|||
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
|
South Korea (Won)
|
|
$
|
4,810
|
|
|
1,141.9
|
|
|
Japan (Yen)
|
|
4,057
|
|
|
112.2
|
|
|
|
China (Yuan Renminbi)
|
|
3,741
|
|
|
6.8
|
|
|
|
European Markets (Euro)
|
|
2,516
|
|
|
0.9
|
|
|
|
Canada (Dollar)
|
|
1,573
|
|
|
1.3
|
|
|
|
Guatemala (Quetzal)
|
|
1,147
|
|
|
7.3
|
|
|
|
Indonesia (Rupiah)
|
|
1,049
|
|
|
13,313.7
|
|
|
|
Other
|
|
6,553
|
|
|
Varies
|
|
|
|
Total foreign denominated cash and cash equivalents
|
|
25,446
|
|
|
|
|
|
|
U.S. dollars held by foreign subsidiaries
|
|
4,201
|
|
|
|
|
|
|
Total cash and cash equivalents held by foreign subsidiaries
|
|
$
|
29,647
|
|
|
|
|
|
Six Months Ended June 30,
|
|
2017
|
|
2016
|
||
|
Canada (Dollar)
|
|
1.3
|
|
|
1.2
|
|
|
European Markets (Euro)
|
|
0.9
|
|
|
0.9
|
|
|
Japan (Yen)
|
|
112.4
|
|
|
120.2
|
|
|
South Korea (Won)
|
|
1,142.0
|
|
|
1,100.6
|
|
|
Item No.
|
|
Exhibit
|
|
3.1(1)
|
|
Amended and Restated Articles of Incorporation, as amended
|
|
3.2(2)
|
|
Amended and Restated Bylaws
|
|
31.1(3)
|
|
Certification of Chief Executive Officer under SEC Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934
|
|
31.2(3)
|
|
Certificate of Chief Financial Officer under SEC Rule 13a-14(a)/15d-14(a) promulgated under the Securities Exchange Act of 1934
|
|
32.1(3)
|
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350
|
|
32.2(3)
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
(1)
|
Previously filed on March 14, 2016, as an exhibit to an Annual Report on Form 10-K and incorporated herein by reference.
|
|
(2)
|
Previously filed on June 1, 2017, as an exhibit to a Current Report on Form 8-K and incorporated herein by reference.
|
|
(3)
|
Filed currently herewith.
|
|
Nature's Sunshine Products, Inc.
|
||
|
|
|
|
|
Date:
|
August 9, 2017
|
/s/ Gregory L. Probert
|
|
|
|
Gregory L. Probert,
|
|
|
|
Chief Executive Officer and Chairman of the Board
|
|
|
|
|
|
|
|
|
|
Date:
|
August 9, 2017
|
/s/ Joseph W. Baty
|
|
|
|
Joseph W. Baty,
|
|
|
|
Executive Vice President, Chief Financial Officer and Treasurer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|